Examkin

Question

Difficulty: HardRheumatology and Immunology

A 68-year-old man is evaluated in the hospital for acute, severe right knee pain. He was admitted 3 days ago for progressive dyspnea, orthopnea, and lower extremity edema. He was diagnosed with acute decompensated heart failure and treated with intravenous furosemide, which significantly improved his respiratory symptoms. His temperature is 38.1°C (100.6°F) and blood pressure is 135/85 mm Hg. Medical history includes ischemic cardiomyopathy and chronic kidney disease. Laboratory studies show a serum creatinine of 2.6 mg/dL (baseline 2.5 mg/dL). Physical examination of the right knee reveals marked erythema, warmth, and a tense joint effusion. Range of motion is severely restricted due to pain. Arthrocentesis yields cloudy yellow synovial fluid containing 55,000 leukocytes/µL (85% neutrophils). Gram stain shows no organisms. Polarized light microscopy demonstrates intracellular, negatively birefringent, needle-shaped crystals. Which of the following is the most appropriate next step in management of this patient's joint pain?

  1. A
    Intravenous vancomycin and ceftriaxone
  2. B
    Oral indomethacin
  3. Intra-articular injection of triamcinoloneAnswer
  4. D
    Oral colchicine
  5. E
    Oral allopurinol

Answer

Intra-articular injection of triamcinolone
This patient is experiencing an acute gout flare, a common complication when loop diuretics (e.g., furosemide) are initiated, as they decrease renal urate excretion. The treatment of acute gout relies on anti-inflammatory agents: NSAIDs, colchicine, or glucocorticoids. However, medical comorbidities strictly dictate the choice of agent. In a patient with advanced chronic kidney disease (CKD) and acute decompensated heart failure, NSAIDs (e.g., indomethacin) are strongly contraindicated because they reduce renal blood flow, acutely worsen kidney function, and promote sodium and water retention. Colchicine is heavily dependent on renal clearance; in advanced CKD, it carries a high risk of fatal neuromyopathy and bone marrow suppression. Therefore, glucocorticoids are the safest option. Because this patient has a monoarticular flare (only the right knee is involved), an intra-articular injection of a glucocorticoid (e.g., triamcinolone) is the most appropriate next step. It provides rapid, targeted relief while minimizing systemic side effects such as hyperglycemia or fluid retention.

Step-by-Step Solution

1
Interpret the arthrocentesis findings to establish a diagnosis.
The synovial fluid shows negatively birefringent, needle-shaped crystals and a negative Gram stain, confirming an acute gout flare and ruling out septic arthritis.
Accurate diagnosis is required before initiating therapy, as gout and septic arthritis can both present with fever, erythema, and high synovial leukocyte counts.
2
Evaluate the patient's comorbidities and current medical status.
The patient has severe chronic kidney disease (creatinine 2.6 mg/dL) and is currently being treated for acute decompensated heart failure.
Comorbidities heavily dictate the choice of pharmacotherapy in acute gout, as standard first-line agents have significant toxicities.
3
Select the optimal pharmacological intervention based on the comorbidity profile.
Intra-articular triamcinolone is chosen because NSAIDs and colchicine are contraindicated or highly dangerous in this patient's clinical context.
NSAIDs worsen CKD and heart failure. Colchicine causes severe toxicity in CKD. Intra-articular glucocorticoids provide potent local anti-inflammatory effects without systemic risks.

Key Concept

Management of acute gout flares requires careful medication selection based on comorbidities; intra-articular glucocorticoids are the treatment of choice for monoarticular flares in patients with advanced CKD or heart failure where NSAIDs and colchicine are contraindicated.
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic